CyTOF profiling of bone marrow immune dynamics across myeloma stages

Dana Cholujova1, Gabor Beke2, Lubos Klucar2

  • 1Department of Tumor Immunology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

Oncoimmunology
|August 18, 2025
PubMed

Insights

Multiple myeloma disrupts immune balance in the bone marrow. Mass cytometry revealed immune cell changes across disease stages, impacting survival and offering targets for immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Multiple myeloma (MM) significantly alters the bone marrow (BM) immune microenvironment.
  • Understanding these immune dynamics is crucial for MM progression and treatment resistance.

Purpose of the Study:

  • To comprehensively characterize the BM immune landscape across different MM stages using mass cytometry (CyTOF).
  • To identify immune profiles associated with clinical outcomes and disease progression.

Main Methods:

  • High-dimensional mass cytometry (CyTOF) profiling of BM samples.
  • Analysis of immune cell populations in MGUS, smoldering MM, and active MM (newly diagnosed and relapsed/refractory).
  • Correspondence analysis to correlate immune profiles with clinical outcomes.

Main Results:

  • Immune remodeling observed across MM progression, with adaptive immune suppression and innate immune infiltration.
  • Distinct alterations in T helper cells, cytotoxic T cells, monocytes, and neutrophils from MGUS to SMM.
  • Active MM shows expanded myeloid/monocytic lineages and reduced B cell populations.
  • Specific immune profiles correlated significantly with progression-free and overall survival.

Conclusions:

  • CyTOF profiling effectively reveals intricate BM immune dynamics in MM.
  • Identified immune signatures provide a foundation for prognostic biomarkers.
  • Findings support the development of tailored precision immunotherapeutic strategies for MM.